Allakos Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Allakos stock.
View analyst ratings for Allakos or view top-rated stocks.

Wall Street analysts have given Allakos a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Allakos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Allakos.

Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings data on Sunday, May, 9th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.18.
View Allakos' earnings history.

Allakos' stock was trading at $58.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALLK stock has increased by 59.6% and is now trading at $93.04.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 12-month price targets for Allakos' stock. Their forecasts range from $145.00 to $230.00. On average, they anticipate Allakos' stock price to reach $197.67 in the next twelve months. This suggests a possible upside of 112.5% from the stock's current price.
View analysts' price targets for Allakos or view top-rated stocks among Wall Street analysts.

Some companies that are related to Allakos include UCB (UCBJF), Catalent (CTLT), Viatris (VTRS), Elanco Animal Health (ELAN), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Ono Pharmaceutical (OPHLF), Maravai LifeSciences (MRVI), CureVac (CVAC), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ) and Arrowhead Pharmaceuticals (ARWR).
View all of ALLK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

(ALLK) raised $96 million in an initial public offering on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.39%), Redmile Group LLC (4.52%), Capital International Investors (4.25%), Baker BROS. Advisors LP (1.31%), Janus Henderson Group PLC (1.02%) and Alliancebernstein L.P. (0.95%). Company insiders that own Allakos stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander and Robert J More.
View institutional ownership trends for Allakos.

ALLK stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Redmile Group LLC, BlackRock Inc., Bank of Montreal Can, Rock Springs Capital Management LP, Cormorant Asset Management LP, Credit Suisse AG, and Baker BROS. Advisors LP. Company insiders that have sold Allakos company stock in the last year include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, and Robert J More.
View insider buying and selling activity for Allakos or view top insider-selling stocks.

ALLK stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Point72 Asset Management L.P., Jennison Associates LLC, Morgan Stanley, Voloridge Investment Management LLC, Moneta Group Investment Advisors LLC, Geode Capital Management LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Allakos or or view top insider-buying stocks.

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALLK stock can currently be purchased for approximately $93.04.

Allakos has a market capitalization of $4.98 billion. The company earns $-153,480,000.00 in net income (profit) each year or ($3.10) on an earnings per share basis.

Allakos employs 141 workers across the globe.

The official website for Allakos is www.allakos.com.

Allakos is headquartered at 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]